Michael Fons

Corporate Officer/Principal at University of Texas Medical Branch

64 year

Health Technology

Consumer Services

Profile

Michael Fons is currently working as an Adjunct Associate Professor at the University of Texas Medical Branch.
Previously, he worked as an Executive Director-Business Development at Vical, Inc. from 2002 to 2004 and as a Vice President-Corporate Development at Inovio Pharmaceuticals, Inc.

Michael Fons active positions

Companies	Position	Start
University of Texas Medical Branch	Corporate Officer/Principal	-

All active positions of Michael Fons

Former positions of Michael Fons

Companies	Position	End
Vical, Inc. Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.	Corporate Officer/Principal	2003-12-31
INOVIO PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

See the detail of Michael Fons's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Fons's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
INOVIO PHARMACEUTICALS, INC.	Health Technology

Private companies	1
Vical, Inc. Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.	Health Technology